{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:53:57Z","timestamp":1792738437631,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.antiviral.2006.07.006","type":"journal-article","created":{"date-parts":[[2006,7,30]],"date-time":"2006-07-30T02:01:00Z","timestamp":1154224860000},"page":"50-59","source":"Crossref","is-referenced-by-count":83,"title":["A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals"],"prefix":"10.1016","volume":"73","author":[{"given":"James W.","family":"Noah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana L.","family":"Noah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Lucile","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen B.","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2006.07.006_bib1","first-page":"15","article-title":"FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection","volume":"17","author":"Bartlett","year":"2005","journal-title":"Hopkins HIV Rep."},{"key":"10.1016\/j.antiviral.2006.07.006_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005\u20132006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2006.07.006_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.dmr.2005.05.002","article-title":"Pandemic influenza: are we ready?","volume":"3","author":"Cinti","year":"2005","journal-title":"Disaster Manage. Response"},{"key":"10.1016\/j.antiviral.2006.07.006_bib4","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2006.07.006_bib5","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa054512","article-title":"Oseltamivir resistance during treatment of influenza A (H5N1) infection","volume":"353","author":"de Jong","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2006.07.006_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/1087057105276474","article-title":"Evaluation of division-arrested cells for cell-based high-throughput screening and profiling","volume":"10","author":"Digan","year":"2005","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.antiviral.2006.07.006_bib7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/AAC.11.6.946","article-title":"Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate","volume":"11","author":"Eriksson","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.07.006_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1592\/phco.26.3.312","article-title":"Pandemics, avian influenza A (H5N1), and a strategy for pharmacists","volume":"26","author":"Ford","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.antiviral.2006.07.006_bib9","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1021\/jm0302593","article-title":"Simple, intuitive calculations of free energy of binding for protein\u2013ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes","volume":"46","author":"Fornabaio","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2006.07.006_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/adt.2005.3.7","article-title":"Improving consistency of cell-based assays by using division-arrested cells","volume":"3","author":"Fursov","year":"2005","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.antiviral.2006.07.006_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.07.006_bib12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1087057105274896","article-title":"Quantitative cell-based high-content screening for vasopressin receptor agonists using transfluor technology","volume":"10","author":"Ghosh","year":"2005","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.antiviral.2006.07.006_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0014-5793(94)01369-C","article-title":"Novel assay for the influenza virus M2 channel activity","volume":"357","author":"Giffin","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2006.07.006_bib14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMc060077","article-title":"Oseltamivir resistance in influenza A (H5N1) infection","volume":"354","author":"Gupta","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2006.07.006_bib15","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1021\/bi027081r","article-title":"Quantitative analysis of influenza virus RNP interaction with RNA cap structures and comparison to human cap binding protein eIF4E","volume":"42","author":"Hooker","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2006.07.006_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ki.1986.7","article-title":"Transport and metabolic functions in cultured renal tubule cells","volume":"29","author":"Horster","year":"1986","journal-title":"Kidney Int."},{"key":"10.1016\/j.antiviral.2006.07.006_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.2001.1181","article-title":"Role of ATP in influenza virus budding","volume":"290","author":"Hui","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2006.07.006_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/js9803205","article-title":"MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening","volume":"88","author":"Irvine","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.antiviral.2006.07.006_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2006.07.006_bib20","first-page":"10","article-title":"Miniaturizing and automating cell viability and reporter assays for high-throughput and ultrahigh-throughput screening","author":"Larson","year":"2004","journal-title":"Cell Notes (Promega)"},{"key":"10.1016\/j.antiviral.2006.07.006_bib21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/nar\/gkg253","article-title":"Activation of influenza virus RNA polymerase by the 5\u2032 and 3\u2032 terminal duplex of genomic RNA","volume":"31","author":"Lee","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2006.07.006_bib22","first-page":"341","article-title":"Antivirals for influenza","volume":"189","author":"Leophonte","year":"2005","journal-title":"Bull. Acad. Natl. Med."},{"key":"10.1016\/j.antiviral.2006.07.006_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","article-title":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon","volume":"44","author":"Markland","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.07.006_bib24","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1128\/JVI.79.6.3595-3605.2005","article-title":"The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging","volume":"79","author":"McCown","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2006.07.006_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jviromet.2005.06.023","article-title":"Use of electric cell\u2013substrate impedance sensing as a tool for quantifying cytopathic effect in influenza A virus infected MDCK cells in real-time","volume":"130","author":"McCoy","year":"2005","journal-title":"J. Virol. Meth."},{"key":"10.1016\/j.antiviral.2006.07.006_bib26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1637\/0005-2086-47.s3.1141","article-title":"Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays","volume":"47","author":"Mungall","year":"2003","journal-title":"Avian Dis."},{"key":"10.1016\/j.antiviral.2006.07.006_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0042-6822(02)00127-7","article-title":"Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3\u2032 end processing of cellular pre-mRNAS","volume":"307","author":"Noah","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2006.07.006_bib28","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1021\/ed082p1552","article-title":"Using visible spectrophotometers and pH measurements to study speciation in a guided-inquiry laboratory","volume":"82","author":"Otto","year":"2005","journal-title":"J. Chem. Ed."},{"key":"10.1016\/j.antiviral.2006.07.006_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1469-0691.2003.00564.x","article-title":"Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors","volume":"9","author":"Oxford","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2006.07.006_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/vim.2005.18.373","article-title":"Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant","volume":"18","author":"Ozaki","year":"2005","journal-title":"Viral Immunol."},{"key":"10.1016\/j.antiviral.2006.07.006_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1126\/science.1122947","article-title":"Emergence of drug-resistant influenza virus: population dynamical considerations","volume":"312","author":"Regoes","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2006.07.006_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00784-004-0259-2","article-title":"Effect of enamel matrix protein derivative on the attachment, proliferation, and viability of human SaOs(2) osteoblasts on titanium implants","volume":"8","author":"Schwarz","year":"2004","journal-title":"Clin. Oral. Investig."},{"key":"10.1016\/j.antiviral.2006.07.006_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/JVI.77.1.481-488.2003","article-title":"Ribavirin causes error catastrophe during Hantaan virus replication","volume":"77","author":"Severson","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2006.07.006_bib34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1128\/AAC.20.6.769","article-title":"Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza type A viruses","volume":"20","author":"Shannon","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.07.006_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2005.06.003","article-title":"In vitro and in vivo influenza virus-inhibitory effects of viramidine","volume":"68","author":"Sidwell","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.07.006_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(00)00125-X","article-title":"In vitro and in vivo assay systems for study of influenza virus inhibitors","volume":"48","author":"Sidwell","year":"2000","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.07.006_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0166-0934(02)00137-4","article-title":"Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds","volume":"106","author":"Smee","year":"2002","journal-title":"J. Virol. Meth."},{"key":"10.1016\/j.antiviral.2006.07.006_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0166-3542(01)00168-1","article-title":"Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201","volume":"52","author":"Smee","year":"2001","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.07.006_bib39","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1128\/AAC.42.12.3234","article-title":"Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071","volume":"42","author":"Tai","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.07.006_bib40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/JVI.76.3.1391-1399.2002","article-title":"Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture","volume":"76","author":"Takeda","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2006.07.006_bib41","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1128\/AAC.38.12.2827","article-title":"Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds","volume":"38","author":"Tomassini","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2006.07.006_bib42","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2006.07.006_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2005.06.006","article-title":"Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors","volume":"67","author":"Westby","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2006.07.006_bib44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354206002075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354206002075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T07:29:49Z","timestamp":1555745389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354206002075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0166354206002075"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2006.07.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}